Kim Min-Ki, Won Dae-Youn, Lee Jin-Kwon, Kang Won-Kyung, Kim Jun-Gi, Oh Seong Taek
Department of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea.
Ann Surg Treat Res. 2015 May;88(5):260-8. doi: 10.4174/astr.2015.88.5.260. Epub 2015 Apr 30.
To investigate the efficacy and safety of the transanal tube (TAT) in preventing anastomotic leak (AL) in rectal cancer surgery.
Clinical data of the patients who underwent curative surgery for mid rectal cancer from February 2010 to February 2014 were reviewed retrospectively. Rectal cancers arising 5 to 10 cm above the anal verge were selected. Patients were divided into the ileostomy, TAT, or no-protection groups. Postoperative complications including AL and postoperative course were compared.
We included 137 patients: 67, 35, and 35 patients were included in the ileostomy, TAT, and no-protection groups, respectively. Operation time was longer in the ileostomy group (P = 0.029), and more estimated blood loss was observed (P = 0.018). AL occurred in 5 patients (7.5%) in the ileostomy group, 1 patients (2.9%) in the TAT group, and 6 patients (17.1%) in the no-protection group (P = 0.125). Patients in the ileostomy group resumed diet more than 1 day earlier than those in the other groups (P = 0.000). Patients in the no-protection group had about 1 or 2 days longer postoperative hospital stay (P = 0.048). The ileostomy group showed higher late complication rates than the other groups as complications associated with the stoma itself or repair operation developed (P = 0.019).
For mid rectal cancer surgery, the TAT supports anastomotic site protection and diverts ileostomy-related complications. Further large scale randomized controlled studies are needed to gain more evidence and expand the range of TAT usage.
探讨经肛门置管(TAT)在直肠癌手术中预防吻合口漏(AL)的有效性和安全性。
回顾性分析2010年2月至2014年2月期间接受根治性中低位直肠癌手术患者的临床资料。选取距肛缘5至10 cm的直肠癌患者。将患者分为回肠造口术组、TAT组或无保护组。比较术后包括AL在内的并发症及术后病程。
共纳入137例患者,回肠造口术组、TAT组和无保护组分别有67例、35例和35例患者。回肠造口术组手术时间较长(P = 0.029),估计失血量较多(P = 0.018)。回肠造口术组有5例患者(7.5%)发生AL,TAT组有1例患者(2.9%)发生AL,无保护组有6例患者(17.1%)发生AL(P = 0.125)。回肠造口术组患者恢复饮食比其他组早1天以上(P = 0.000)。无保护组患者术后住院时间长约1或2天(P = 0.048)。回肠造口术组晚期并发症发生率高于其他组,因为出现了与造口本身或修复手术相关的并发症(P = 0.019)。
对于中低位直肠癌手术,TAT有助于保护吻合口并避免回肠造口相关并发症。需要进一步开展大规模随机对照研究以获取更多证据并扩大TAT的应用范围。